[13C]glucose breath testing provides a noninvasive measure of insulin resistance: Calibration analyses against clamp studies

Maysa Hussain, Morteza Jangorbhani, Sally Schuette, Robert Considine, Robin L. Chisholm, Kieren Mather

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Exhaled 13CO2 following ingestion of [13C]glucose with a standard oral glucose tolerance load correlates with blood glucose values but is determined by tissue glucose uptake. Therefore exhaled 13CO2 may also be a surrogate measure of the whole-body glucose disposal rate (GDR) measured by the gold standard hyperinsulinemic euglycemic clamp. Subjects and Methods: Subjects from across the glycemia range were studied on 2 consecutive days under fasting conditions. On Day 1, a 75-g oral glucose load spiked with [13C]glucose was administered. On Day 2, a hyperinsulinemic euglycemic clamp was performed. Correlations between breath parameters and clamp-derived GDR were evaluated, and calibration analyses were performed to evaluate the precision of breath parameter predictions of clamp measures. Results: Correlations of breath parameters with GDR and GDR per kilogram of fat-free mass (GDRffm) ranged from 0.54 to 0.61 and 0.54 to 0.66, respectively (all P<0.001). In calibration analyses the root mean square error for breath parameters predicting GDR and GDRffm ranged from 2.32 to 2.46 and from 3.23 to 3.51, respectively. Cross-validation prediction error (CVPE) estimates were 2.35-2.51 (GDR) and 3.29-3.57 (GDRffm). Prediction precision of breath enrichment at 180 min predicting GDR (CVPE=2.35) was superior to that for inverse insulin (2.68) and the Matsuda Index (2.51) but inferior to that for the log of homeostasis model assessment (2.21) and Quantitative Insulin Sensitivity Check Index (2.29) (all P<10-5). Similar patterns were seen for predictions of GDRffm. Conclusions: 13CO2 appearance in exhaled breath following a standard oral glucose load with added [13C]glucose provides a valid surrogate index of clamp-derived measures of whole-body insulin resistance, with good accuracy and precision. This noninvasive breath test-based approach can provide a useful measure of whole-body insulin resistance in physiologic and epidemiologic studies.

Original languageEnglish
Pages (from-to)102-112
Number of pages11
JournalDiabetes Technology and Therapeutics
Volume16
Issue number2
DOIs
StatePublished - Feb 1 2014

Fingerprint

Calibration
Insulin Resistance
Glucose
Body Weights and Measures
Glucose Clamp Technique
Fats
Breath Tests
Glucose Tolerance Test
Blood Glucose
Epidemiologic Studies
Fasting
Homeostasis
Eating
Insulin

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Medical Laboratory Technology
  • Medicine(all)

Cite this

[13C]glucose breath testing provides a noninvasive measure of insulin resistance : Calibration analyses against clamp studies. / Hussain, Maysa; Jangorbhani, Morteza; Schuette, Sally; Considine, Robert; Chisholm, Robin L.; Mather, Kieren.

In: Diabetes Technology and Therapeutics, Vol. 16, No. 2, 01.02.2014, p. 102-112.

Research output: Contribution to journalArticle

@article{bc39f8410b7e4c0c99edcdcb127c9491,
title = "[13C]glucose breath testing provides a noninvasive measure of insulin resistance: Calibration analyses against clamp studies",
abstract = "Background: Exhaled 13CO2 following ingestion of [13C]glucose with a standard oral glucose tolerance load correlates with blood glucose values but is determined by tissue glucose uptake. Therefore exhaled 13CO2 may also be a surrogate measure of the whole-body glucose disposal rate (GDR) measured by the gold standard hyperinsulinemic euglycemic clamp. Subjects and Methods: Subjects from across the glycemia range were studied on 2 consecutive days under fasting conditions. On Day 1, a 75-g oral glucose load spiked with [13C]glucose was administered. On Day 2, a hyperinsulinemic euglycemic clamp was performed. Correlations between breath parameters and clamp-derived GDR were evaluated, and calibration analyses were performed to evaluate the precision of breath parameter predictions of clamp measures. Results: Correlations of breath parameters with GDR and GDR per kilogram of fat-free mass (GDRffm) ranged from 0.54 to 0.61 and 0.54 to 0.66, respectively (all P<0.001). In calibration analyses the root mean square error for breath parameters predicting GDR and GDRffm ranged from 2.32 to 2.46 and from 3.23 to 3.51, respectively. Cross-validation prediction error (CVPE) estimates were 2.35-2.51 (GDR) and 3.29-3.57 (GDRffm). Prediction precision of breath enrichment at 180 min predicting GDR (CVPE=2.35) was superior to that for inverse insulin (2.68) and the Matsuda Index (2.51) but inferior to that for the log of homeostasis model assessment (2.21) and Quantitative Insulin Sensitivity Check Index (2.29) (all P<10-5). Similar patterns were seen for predictions of GDRffm. Conclusions: 13CO2 appearance in exhaled breath following a standard oral glucose load with added [13C]glucose provides a valid surrogate index of clamp-derived measures of whole-body insulin resistance, with good accuracy and precision. This noninvasive breath test-based approach can provide a useful measure of whole-body insulin resistance in physiologic and epidemiologic studies.",
author = "Maysa Hussain and Morteza Jangorbhani and Sally Schuette and Robert Considine and Chisholm, {Robin L.} and Kieren Mather",
year = "2014",
month = "2",
day = "1",
doi = "10.1089/dia.2013.0151",
language = "English",
volume = "16",
pages = "102--112",
journal = "Diabetes Technology and Therapeutics",
issn = "1520-9156",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - [13C]glucose breath testing provides a noninvasive measure of insulin resistance

T2 - Calibration analyses against clamp studies

AU - Hussain, Maysa

AU - Jangorbhani, Morteza

AU - Schuette, Sally

AU - Considine, Robert

AU - Chisholm, Robin L.

AU - Mather, Kieren

PY - 2014/2/1

Y1 - 2014/2/1

N2 - Background: Exhaled 13CO2 following ingestion of [13C]glucose with a standard oral glucose tolerance load correlates with blood glucose values but is determined by tissue glucose uptake. Therefore exhaled 13CO2 may also be a surrogate measure of the whole-body glucose disposal rate (GDR) measured by the gold standard hyperinsulinemic euglycemic clamp. Subjects and Methods: Subjects from across the glycemia range were studied on 2 consecutive days under fasting conditions. On Day 1, a 75-g oral glucose load spiked with [13C]glucose was administered. On Day 2, a hyperinsulinemic euglycemic clamp was performed. Correlations between breath parameters and clamp-derived GDR were evaluated, and calibration analyses were performed to evaluate the precision of breath parameter predictions of clamp measures. Results: Correlations of breath parameters with GDR and GDR per kilogram of fat-free mass (GDRffm) ranged from 0.54 to 0.61 and 0.54 to 0.66, respectively (all P<0.001). In calibration analyses the root mean square error for breath parameters predicting GDR and GDRffm ranged from 2.32 to 2.46 and from 3.23 to 3.51, respectively. Cross-validation prediction error (CVPE) estimates were 2.35-2.51 (GDR) and 3.29-3.57 (GDRffm). Prediction precision of breath enrichment at 180 min predicting GDR (CVPE=2.35) was superior to that for inverse insulin (2.68) and the Matsuda Index (2.51) but inferior to that for the log of homeostasis model assessment (2.21) and Quantitative Insulin Sensitivity Check Index (2.29) (all P<10-5). Similar patterns were seen for predictions of GDRffm. Conclusions: 13CO2 appearance in exhaled breath following a standard oral glucose load with added [13C]glucose provides a valid surrogate index of clamp-derived measures of whole-body insulin resistance, with good accuracy and precision. This noninvasive breath test-based approach can provide a useful measure of whole-body insulin resistance in physiologic and epidemiologic studies.

AB - Background: Exhaled 13CO2 following ingestion of [13C]glucose with a standard oral glucose tolerance load correlates with blood glucose values but is determined by tissue glucose uptake. Therefore exhaled 13CO2 may also be a surrogate measure of the whole-body glucose disposal rate (GDR) measured by the gold standard hyperinsulinemic euglycemic clamp. Subjects and Methods: Subjects from across the glycemia range were studied on 2 consecutive days under fasting conditions. On Day 1, a 75-g oral glucose load spiked with [13C]glucose was administered. On Day 2, a hyperinsulinemic euglycemic clamp was performed. Correlations between breath parameters and clamp-derived GDR were evaluated, and calibration analyses were performed to evaluate the precision of breath parameter predictions of clamp measures. Results: Correlations of breath parameters with GDR and GDR per kilogram of fat-free mass (GDRffm) ranged from 0.54 to 0.61 and 0.54 to 0.66, respectively (all P<0.001). In calibration analyses the root mean square error for breath parameters predicting GDR and GDRffm ranged from 2.32 to 2.46 and from 3.23 to 3.51, respectively. Cross-validation prediction error (CVPE) estimates were 2.35-2.51 (GDR) and 3.29-3.57 (GDRffm). Prediction precision of breath enrichment at 180 min predicting GDR (CVPE=2.35) was superior to that for inverse insulin (2.68) and the Matsuda Index (2.51) but inferior to that for the log of homeostasis model assessment (2.21) and Quantitative Insulin Sensitivity Check Index (2.29) (all P<10-5). Similar patterns were seen for predictions of GDRffm. Conclusions: 13CO2 appearance in exhaled breath following a standard oral glucose load with added [13C]glucose provides a valid surrogate index of clamp-derived measures of whole-body insulin resistance, with good accuracy and precision. This noninvasive breath test-based approach can provide a useful measure of whole-body insulin resistance in physiologic and epidemiologic studies.

UR - http://www.scopus.com/inward/record.url?scp=84892644070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892644070&partnerID=8YFLogxK

U2 - 10.1089/dia.2013.0151

DO - 10.1089/dia.2013.0151

M3 - Article

C2 - 24116833

AN - SCOPUS:84892644070

VL - 16

SP - 102

EP - 112

JO - Diabetes Technology and Therapeutics

JF - Diabetes Technology and Therapeutics

SN - 1520-9156

IS - 2

ER -